Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma | NEJM
Belantamab mafodotin had single-agent activity in patients with relapsed or refractory multiple myeloma, a finding that supports further evaluation of the agent in combination with standard-care th…